BiotechTube
GigaMune

GigaMune

San Diego, United States· Est.
gigamune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

GigaMune is an early-stage biotech pioneering a novel approach to cell therapy by developing in vivo treatments, eliminating the need for ex vivo cell manufacturing. The company leverages a proprietary technology platform combining powerful bioinformatics algorithms, high-throughput genomics, and artificial intelligence to design targeted viral delivery vectors and therapeutic CAR constructs. Its initial pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease. Founded by serial entrepreneurs and backed by multiple SBIR grants, GigaMune is positioned to address significant access and scalability challenges in the cell therapy field.

OncologyGenetic Diseases

Technology Platform

Integrated computational and experimental platform using advanced bioinformatics algorithms, high-throughput genomics, and AI to design targeted viral gene delivery vectors and optimize chimeric antigen receptors (CARs) for in vivo cell therapy.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

The in vivo cell therapy market represents a massive opportunity to expand patient access and reduce the cost of advanced treatments by eliminating complex ex vivo manufacturing.
Success in this paradigm could position GigaMune as a platform leader, attracting lucrative partnerships with large pharmaceutical companies.
The growing validation of gene therapy for blood disorders and cancer creates a receptive clinical and regulatory environment for innovative approaches.

Risk Factors

The core technology of targeted in vivo gene delivery to specific immune or stem cells is highly challenging and unproven at scale, posing significant technical risk.
The company faces intense competition from both established ex vivo therapies and other well-funded startups pursuing similar in vivo approaches.
Reliance on grant funding is unsustainable for long-term clinical development, creating financial risk ahead of a necessary major equity financing.

Competitive Landscape

GigaMune competes in the emerging in vivo cell therapy space with companies like Capstan Therapeutics, Ensoma, Umoja Biopharma, and Poseida Therapeutics. It also indirectly competes with approved ex vivo CAR-T leaders (e.g., Novartis, Gilead, Bristol Myers Squibb) and gene therapy companies for blood disorders (Vertex/CRISPR, Bluebird Bio). Differentiation hinges on the specificity and efficiency of its proprietary targeting platform.

More companies in Cell & Gene Therapy →More companies in United States →